When: Confirmed close above $268.93 on volume ≥4.5M shares

Then: Add 50% of target position (~1.5-2.0% portfolio)

When: Successful retest of $269 holding as new support OR acceleration above $275 on follow-through

Then: Add remaining 25% of target position (~0.75-1.0% portfolio)

HOLD and wait for either a pullback entry at $258-$260 or a confirmed breakout above $268.93 with volume before initiating or adding to positions

• MACD histogram collapsed from +0.53 on September 22 to +0.08 today, representing 85%+ momentum loss while price made marginally higher highs — textbook bearish divergence
• TTM PE of 74x is distorted by $5.07 billion in impairment charges in 2025 alone; normalized earnings not yet validated by clean quarterly prints
• Initiating at $263 with $248 stop creates $15 risk vs only $5 reward to resistance at $268.93 — a 1:0.33 risk/reward ratio
• Pullback entry at $258-$260 would offer $10-12 risk vs $7-9 reward to resistance, materially better risk-adjusted positioning
• Aggressive position sizing recommendation of 2%+ before breakout confirmation contradicts the research plan's own 'not a chase' directive
• Q3 earnings is a binary outcome event — pre-positioning ahead of binary catalysts is gambling, not risk management
• 'Higher for longer' rate environment is a double-edged sword: rising discount rates compress pipeline NPV multiples
• ABBV 2.6% yield with 0.28 beta provides defensive support but does not justify aggressive entry at current levels

→ vs aggressive: ATR compression is not a 'coiled spring' — compressed ATR precedes breakouts in both directions, not just higher. This is survivorship bias disguised as technical analysis.

→ vs aggressive: Framing the $258-$260 entry as 'waiting for a free entry' is a false dichotomy — the stock could pull back below $248, triggering stops and offering a much better risk/reward than current levels.

→ vs aggressive: The 'absence of news is not absence of catalyst' argument is a dangerous inversion — the neutral sentiment reading confirmed zero institutional headlines, zero retail chatter, no pipeline readouts, no FDA actions, no M&A activity.

→ vs aggressive: Doubling position size from 0.75% to 2%+ before confirmation violates the research plan's own entry discipline. 'Conviction' is not a justification for abandoning internal risk rules.

→ vs aggressive: The 30-year yield blowout scenario creates a supply-side headwind on equity valuations that the aggressive analyst completely ignores while only citing the defensive yield demand side.

Maintain HOLD; do not initiate at $263; prepare to scale in on two defined triggers: (1) pullback to $258-$260 with bullish reversal candle at 50 SMA using 25% tranche (0.75-1.0% of portfolio), (2) confirmed close above $268.93 on elevated volume adding another 25% tranche (total 1.5-2.0%). Q3 earnings serve as binary catalyst for full position authorization.

• Entry at $263 with stop at $248 yields $15 risk per share; $275 target = $12 upside (1:0.8 R/R), $280 target = $17 upside (1:1.13 R/R) — aggressive analyst overstated R/R by 30-50%
• MACD histogram collapsed from +0.53 on September 22 to +0.08 — momentum exhaustion, not consolidation energy building
• Aggressive analyst's position sizing violates explicit research plan guidance against initiating at $263
• Q2 2026 shows fundamental regime change: Revenue +10.2% YoY, EPS $2.03 vs $0.10 year-prior, Skyrizi/Rinvoq at $30B combined run-rate growing 40%+
• Conservative analyst too rigid demanding multiple clean quarters when Q2 2026 already validates normalization thesis
• Macro mixed but net slightly supportive: 2.6% yield with 0.28 beta attracts defensive capital in higher-for-longer, but long end expansion creates pipeline NPV headwinds
• Sentiment null reading (zero institutional/retail headlines) is mildly constructive — no crowded positioning to unwind
• HOLD only preserves optionality if triggers are executed when fired; position second tranche more aggressively on confirmation
• Q3 EPS target north of $2.00 and double-digit revenue growth would authorize full position regardless of technical trigger

→ vs aggressive: R/R math overstated by 30-50%; position sizing proposal violates research plan discipline and explicit guidance not to initiate at $263

→ vs aggressive: MACD momentum exhaustion contradicts coiled spring breakout thesis; momentum fading, not building

→ vs conservative: Dismissal of Q2 2026 structural inflection too rigid; 10.2% YoY revenue and EPS normalization represent regime change, not noise

→ vs conservative: Demanding two to three more clean quarters before engaging is overly rigid given Q2 2026 already substantially confirms thesis

→ vs conservative: Framing HOLD as a 'strategy' is sloppy; HOLD is a state, and the actual strategy requires defined triggers and commitment to act on them

→ vs conservative: Treating sentiment null reading as cautionary is incorrect; silent tape is structurally advantageous with no crowded positioning to unwind